Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Xencor, Inc.
ISIN US98401F1057
|WKN A1W96L
Market cap (in EUR)
739 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
Healthcare Biopharmaceuticals Other Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 739 m |
| EPS, EUR | -1.10 |
| P/B ratio | 1.3 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | 111 m |
| Net income, EUR | -81 m |
| Profit margin | -73.20% |
What ETF is Xencor, Inc. in?
There are 3 ETFs which contain Xencor, Inc.. All of these ETFs are listed in the table below. The ETF with the largest weighting of Xencor, Inc. is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.07% | Equity United States Health Care Biotech | 47 |
| iShares S&P SmallCap 600 UCITS ETF | 0.06% | Equity United States Small Cap | 2,254 |
| JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) | 0.01% | Equity United States Small Cap | 187 |
Latest articles
— Gegevens verstrekt door Trackinsight, etfinfo, Xignite Inc., gettex, FactSet en justETF GmbH.
Standaard zijn ETF-rendementen inclusief dividenduitkeringen (indien van toepassing). Er is geen garantie voor de volledigheid, juistheid en correctheid van de getoonde informatie.